ACR/ARHP Annual Meeting 2015
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.
Asthma management in youths and adults 12 years of age and older classified by asthma severity.
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
ACR 2019, News
Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
The GOLD Report includes key recommendations for personalizing treatment in stable COPD as well as guidelines for managing exacerbations.
The most recent guidelines from the American College of Rheumatology
include pharmacologic and nonpharmacologic therapy for hyperuricemia.
The recommendations for asthma management during pregnancy and lactation are presented in this table.
Recommendations for the management of severe asthma from the Global Initiative for Asthma (GINA).